Alfred E. Tiefenbacher (gmbh & Co. Kg) opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Alfred E. Tiefenbacher (gmbh & Co. Kg)

Patent Number:
Title:
New Use
Applicant:
Opposition Date:
Jun 25, 2024
Patent Number:
Title:
Pharmaceutical Preparation
Opposition Date:
Jun 5, 2024
Patent Number:
Title:
Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations
Applicant:
Opposition Date:
Mar 1, 2024
Patent Number:
Title:
Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure
Applicant:
Opposition Date:
Dec 7, 2023
Patent Number:
Title:
Treatment Regimen Utilizing Neratinib For Breast Cancer
Applicant:
Opposition Date:
Nov 28, 2023
Patent Number:
Title:
Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole
Applicant:
Opposition Date:
Aug 3, 2022
Patent Number:
Title:
Formulations Of Enzalutamide
Opposition Date:
May 18, 2022
Patent Number:
Title:
Pharmaceutical Composition Containing Rifaximin Alpha & Delta
Applicant:
Opposition Date:
Apr 6, 2022
Patent Number:
Title:
Sustained-Release Dosage Forms Of Ruxolitinib
Opposition Date:
Feb 28, 2022
Patent Number:
Title:
Nep Inhibitors For Treating Diseases Characterized By Atrial Enlargement Or Remodeling
Applicant:
Opposition Date:
Jan 26, 2022

Latest patents of Alfred E. Tiefenbacher (gmbh & Co. Kg) opposed by its competitors

Patent:
Grant Date:
Jul 20, 2022
Title:
Microparticulate Varenicline Citrate
Oppositions:
1
Patent:
Grant Date:
Jun 24, 2020
Title:
Pharmaceutical Composition Comprising Eltrombopag Olamine, Reducing Sugar, And Polymeric Binder
Oppositions:
1
Patent:
Grant Date:
Aug 21, 2019
Title:
Pharmaceutical Tablet Composition Comprising Eltrombopag Olamine
Oppositions:
1

Competitors of Alfred E. Tiefenbacher (gmbh & Co. Kg)

NOVARTIS AG

ALCON RESEARCH, LTD.

SANDOZ AG

Want to track Alfred E. Tiefenbacher (gmbh & Co. Kg)?

Feel free to send us a message here and we will get back to you